The percentages of AAV integrations in the Cas9-treated AMD mice were approximately 11.0% and 13.3% at the Vegfa-sg1 and Vegfa-sg2 target sites, respectively, when normalized to total sequenced events (Fig. 4c). The gene discussed is VEGFA; the disease is age-related macular degeneration.